FDA approves Viatris' low-dose estrogen weekly patch?

7.5 Pkt. (24h)Health & MedicineWeekly2T

PolymarketVerfügbarkeit prüfenKein KYC2% GebührVerifizierte AuflösungsdatenOrdentlich kalibriert

Aktuelle implizite Wahrscheinlichkeit

Ja 67%-0.1pt

Marktqualitat

32 / 100

Niedrige Qualität

24h-Volumen

0 €

Liquidität

104,9 €

Niedrige Liquidität

Geld / Brief

46.0% / 88.0%

Spread

42.0 pt

Breiter Spread

7d-Änderung

+12.0 pts

Marktdaten

Aktualisiert vor 19 Minuten

1. Juli 26, 6:1430. Juli 26, 17:59

Trends

Ergebnis24hWahrscheinlichkeit

Nur virtuelles Guthaben – kein echtes GeldKeine Finanzberatung

Gewähltes Ergebnis

Yes67%

Einsatz (USDT)

Regeln

As of market creation, the FDA's expected decision date for the specified application is July 30, 2026.

This market will resolve to "Yes" if the U.S.
Food and Drug Administration (FDA) grants full or conditional approval for Viatris's low-dose estrogen weekly patch for contraception by August 13, 2026, 11:59 PM ET.
Otherwise, this market will resolve to "No."
An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs

Volumentrend

2. Juli20T Daten21. Juli

Verwandte Märkte

Will AbbVie Q2 Global Skyrizi net revenues be above __?

0 €

$18B: 45%

POLYMARKET

What price will Bitcoin hit July 27-August 2?

30.718,1 €

↓ 62,000: 52%

POLYMARKET

What price will Ethereum hit July 27-August 2?

3914,1 €

↓ 1,900: 100%

POLYMARKET

Price of NVIDIA H100 SXM compute by Jul 31, 2026?

3797,6 €

Above $2.71: 50%

KALSHI

Chipotle chicken burrito price in July 2026

3453,9 €

At least $9.79: 3%

KALSHI

Price of NVIDIA B200 compute by Jul 31, 2026?

2865,8 €

Above $6.96: 12%

KALSHI

In diesen Themen aktiv

EthereumETH$1,880.93-4.45%

BitcoinBTC$63,460.23-2.81%

SolanaSOL$73.15-4.45%

XRPXRP$1.05-4.85%

BNBBNB$565.02-1.74%

DogecoinDOGE$0.0701-3.78%

Verwandte Nachrichten

NVIDIA BioNeMo Toolkit Accelerates AI-Driven Drug DiscoveryBlockchain.News

OpenAI Launches GeneBench-Pro to Test AI in BiologyBlockchain.News

Google Transfers Open Health Stack to Linux FoundationBlockchain.News

Regeln

As of market creation, the FDA's expected decision date for the specified application is July 30, 2026.

This market will resolve to "Yes" if the U.S.
Food and Drug Administration (FDA) grants full or conditional approval for Viatris's low-dose estrogen weekly patch for contraception by August 13, 2026, 11:59 PM ET.
Otherwise, this market will resolve to "No."
An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs

FDA approves Viatris' low-dose estrogen weekly patch?

7.5 Pkt. (24h)Health & MedicineWeekly2T

PolymarketVerfügbarkeit prüfenKein KYC2% GebührVerifizierte AuflösungsdatenOrdentlich kalibriert

Aktuelle implizite Wahrscheinlichkeit

Ja 67%-0.1pt

Marktqualitat

32 / 100

Niedrige Qualität

24h-Volumen

0 €

Liquidität

104,9 €

Niedrige Liquidität

Geld / Brief

46.0% / 88.0%

Spread

42.0 pt

Breiter Spread

7d-Änderung

+12.0 pts

Marktdaten

Aktualisiert vor 19 Minuten

1. Juli 26, 6:1430. Juli 26, 17:59

Trends

Ergebnis24hWahrscheinlichkeit

Nur virtuelles Guthaben – kein echtes GeldKeine Finanzberatung

Gewähltes Ergebnis

Yes67%

Einsatz (USDT)

Regeln

As of market creation, the FDA's expected decision date for the specified application is July 30, 2026.

This market will resolve to "Yes" if the U.S.
Food and Drug Administration (FDA) grants full or conditional approval for Viatris's low-dose estrogen weekly patch for contraception by August 13, 2026, 11:59 PM ET.
Otherwise, this market will resolve to "No."
An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs

Volumentrend

2. Juli20T Daten21. Juli

Verwandte Märkte

Will AbbVie Q2 Global Skyrizi net revenues be above __?

0 €

$18B: 45%

POLYMARKET

What price will Bitcoin hit July 27-August 2?

30.718,1 €

↓ 62,000: 52%

POLYMARKET

What price will Ethereum hit July 27-August 2?

3914,1 €

↓ 1,900: 100%

POLYMARKET

Price of NVIDIA H100 SXM compute by Jul 31, 2026?

3797,6 €

Above $2.71: 50%

KALSHI

Chipotle chicken burrito price in July 2026

3453,9 €

At least $9.79: 3%

KALSHI

Price of NVIDIA B200 compute by Jul 31, 2026?

2865,8 €

Above $6.96: 12%

KALSHI

In diesen Themen aktiv

EthereumETH$1,880.93-4.45%

BitcoinBTC$63,460.23-2.81%

SolanaSOL$73.15-4.45%

XRPXRP$1.05-4.85%

BNBBNB$565.02-1.74%

DogecoinDOGE$0.0701-3.78%

Verwandte Nachrichten

NVIDIA BioNeMo Toolkit Accelerates AI-Driven Drug DiscoveryBlockchain.News

OpenAI Launches GeneBench-Pro to Test AI in BiologyBlockchain.News

Google Transfers Open Health Stack to Linux FoundationBlockchain.News

Regeln

As of market creation, the FDA's expected decision date for the specified application is July 30, 2026.

This market will resolve to "Yes" if the U.S.
Food and Drug Administration (FDA) grants full or conditional approval for Viatris's low-dose estrogen weekly patch for contraception by August 13, 2026, 11:59 PM ET.
Otherwise, this market will resolve to "No."
An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs